SCHEMBL14978902

SCHEMBL14978902

COCCOC(=O)N1CCCC(N2CCC(C(=O)NCC(C)C)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 5/20 0.53
CHRM2 P08172 4/20 0.39
CHRM4 P08173 1/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP3A4 P08684 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14978772 0.91 CHRM1 (0.56) CHRM1CHRM2CHRM4KMT2ALMNA
SCHEMBL14978900 0.90 CHRM1 (0.53) CHRM1CHRM2CHRM4KMT2ALMNA
SCHEMBL14978775 0.89 CHRM1 (0.65) CHRM1CHRM2CHRM4LMNATP53
SCHEMBL14964864 0.89 CHRM1 (0.65) CHRM1CHRM2CHRM4LMNATP53
SCHEMBL14978767 0.89 CHRM1 (0.65) CHRM1CHRM2CHRM4LMNATP53
SCHEMBL14964766 0.85 CHRM1 (0.53) CHRM1CHRM2CHRM4KMT2ALMNA
SCHEMBL14978777 0.84 CHRM1 (0.52) CHRM1CHRM2CHRM4KMT2ALMNA
SCHEMBL16217918 0.84 CHRM1 (0.59) CHRM1CHRM2CHRM4KMT2ATP53
SCHEMBL14978888 0.84 CHRM1 (0.62) CHRM1CHRM2KMT2ALMNAHTT
SCHEMBL14978809 0.84 CHRM1 (0.50) CHRM1KMT2ALMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793817-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-10-24 US disclosed
US-11793817-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-10-24 US disclosed
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2021-11-18 US disclosed
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US disclosed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US disclosed
US-10413553-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-09-17 US disclosed
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-07 US disclosed
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-07 US disclosed
US-9907805-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-03-06 US disclosed
US-9907805-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-03-06 US disclosed
US-9573929-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-21 US disclosed
US-9573929-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-21 US disclosed
EP-2780015-B1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2017-01-04 EP disclosed
US-20160068508-A1 Muscarinic M1 Receptor Agonists NXERA PHARMA UK LIMITED (GB) 2016-03-10 US disclosed
US-20160068508-A1 Muscarinic M1 Receptor Agonists NXERA PHARMA UK LIMITED (GB) 2016-03-10 US disclosed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US disclosed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US disclosed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US disclosed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US disclosed
WO-2013072705-A1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-20160068508-A1 Muscarinic M1 Receptor Agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-10973832-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-10413553-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885
US-11793817-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885CHRM2 2/4885CHRM4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.